Novamab focuses on the research and development of new nanobodies.
Novamab focuses on the research and development of new nanobodies. The core members of the team have 15 years of experience in nanobody research and development, and are domestic nanobody "pioneers". At present, they have established an inhaled macromolecular drug research and development platform, an albumin nanobody long-acting platform and a nanobody double-antibody platform, etc., to give full play to nanobody The advantages of antibodies, the development of innovative nanobody drugs such as sprays and eye drops, to solve the pain points of clinical major chronic diseases in terms of administration methods, administration cycles, etc.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 12, 2021 | Series A | ¥100M | 2 | Tianhui Chuangtou | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Tianhui Chuangtou | Yes | Series A |
Tigeryeah Capital | — | Series A |